{"id":"https://openalex.org/W24568803","doi":null,"title":"Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.","display_name":"Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.","publication_year":2008,"publication_date":"2008-02-01","ids":{"openalex":"https://openalex.org/W24568803","mag":"24568803","pmid":"https://pubmed.ncbi.nlm.nih.gov/18246520"},"language":"en","primary_location":{"id":"pmid:18246520","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18246520","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060271747","display_name":"Paschalis I. Vergidis","orcid":"https://orcid.org/0000-0002-6581-3956","observed_orcids":["https://orcid.org/0000-0002-6581-3956"]},"institutions":[{"id":"https://openalex.org/I4210167199","display_name":"Alfa Institute of Biomedical Sciences","ror":"https://ror.org/05pkanq60","country_code":"GR","type":"nonprofit","lineage":["https://openalex.org/I4210167199"]}],"countries":["GR"],"is_corresponding":false,"raw_author_name":"Paschalis I Vergidis","raw_affiliation_strings":["Alfa Institute of Biomedical Sciences, 9 Neapoleos Street, 151 23 Marousi, Athens, Greece"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alfa Institute of Biomedical Sciences, 9 Neapoleos Street, 151 23 Marousi, Athens, Greece","institution_ids":["https://openalex.org/I4210167199"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047582800","display_name":"Matthew E. Falagas","orcid":"https://orcid.org/0000-0002-5905-2695","observed_orcids":["https://orcid.org/0000-0002-5905-2695","https://orcid.org/0000-0002-8068-8575"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew E Falagas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.9935,"has_fulltext":false,"cited_by_count":43,"citation_normalized_percentile":{"value":0.94649178,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"9","issue":"2","first_page":"176","last_page":"83"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multidrug-resistant-gram-negative-bacteria","display_name":"multidrug-resistant Gram-negative bacteria","score":0.9639999866485596},{"id":"https://openalex.org/keywords/antimicrobial-resistance","display_name":"antimicrobial resistance","score":0.699999988079071},{"id":"https://openalex.org/keywords/cephalosporins","display_name":"cephalosporins","score":0.8489999771118164},{"id":"https://openalex.org/keywords/ceftobiprole","display_name":"ceftobiprole","score":0.9679999947547913},{"id":"https://openalex.org/keywords/ceftaroline","display_name":"ceftaroline","score":0.9710000157356262},{"id":"https://openalex.org/keywords/tigecycline","display_name":"tigecycline","score":0.9940000176429749},{"id":"https://openalex.org/keywords/glycylcyclines","display_name":"glycylcyclines","score":0.9480000138282776},{"id":"https://openalex.org/keywords/carbapenems","display_name":"carbapenems","score":0.9940000176429749},{"id":"https://openalex.org/keywords/doripenem","display_name":"doripenem","score":0.9100000262260437},{"id":"https://openalex.org/keywords/faropenem","display_name":"faropenem","score":0.9950000047683716},{"id":"https://openalex.org/keywords/polymyxins","display_name":"polymyxins","score":0.9869999885559082},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8320000171661377},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9929999709129333},{"id":"https://openalex.org/keywords/antimicrobial-peptides","display_name":"antimicrobial peptides","score":0.9490000009536743},{"id":"https://openalex.org/keywords/efflux-pump-inhibitors","display_name":"efflux pump inhibitors","score":1.0}],"concepts":[{"id":"https://openalex.org/C2777027569","wikidata":"https://www.wikidata.org/wiki/Q420595","display_name":"Tigecycline","level":3,"score":0.7651095390319824},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.7110903263092041},{"id":"https://openalex.org/C4937899","wikidata":"https://www.wikidata.org/wiki/Q68541106","display_name":"Antimicrobial","level":2,"score":0.6659122705459595},{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.5917303562164307},{"id":"https://openalex.org/C2780675486","wikidata":"https://www.wikidata.org/wiki/Q423765","display_name":"Polymyxin","level":3,"score":0.5872617959976196},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45044460892677307},{"id":"https://openalex.org/C2777821550","wikidata":"https://www.wikidata.org/wiki/Q411552","display_name":"Doripenem","level":5,"score":0.44282451272010803},{"id":"https://openalex.org/C94665300","wikidata":"https://www.wikidata.org/wiki/Q63391344","display_name":"Antibiotic resistance","level":3,"score":0.3840125799179077},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.37245216965675354},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37073296308517456},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3094370663166046},{"id":"https://openalex.org/C2779375183","wikidata":"https://www.wikidata.org/wiki/Q421670","display_name":"Meropenem","level":4,"score":0.11146324872970581}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006033","descriptor_name":"Glycylglycine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006033","descriptor_name":"Glycylglycine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006033","descriptor_name":"Glycylglycine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006090","descriptor_name":"Gram-Negative Bacteria","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011113","descriptor_name":"Polymyxins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011113","descriptor_name":"Polymyxins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015780","descriptor_name":"Carbapenems","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015780","descriptor_name":"Carbapenems","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016905","descriptor_name":"Gram-Negative Bacterial Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D024901","descriptor_name":"Drug Resistance, Multiple, Bacterial","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:18246520","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18246520","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:24568803","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18246520","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2936185577","https://openalex.org/W2898130317","https://openalex.org/W2302268482","https://openalex.org/W2015542817","https://openalex.org/W2944627110","https://openalex.org/W2087621082","https://openalex.org/W2108314859","https://openalex.org/W3041403610","https://openalex.org/W3007456487","https://openalex.org/W2184658147"],"abstract_inverted_index":{"Gram-negative":[0,49,88,112,135],"bacterial":[1,50,113],"infections":[2,51],"constitute":[3],"an":[4,103],"emerging":[5],"threat":[6],"because":[7,129],"of":[8,11,19,47,69,85,130,147,161,167,186],"the":[9,23,42,45,53,61,83,92,97,145,179,184],"development":[10,25],"multidrug-resistant":[12,87,111],"organisms.":[13,89,136],"There":[14],"is":[15,60,189],"a":[16,66],"relative":[17],"shortage":[18],"new":[20,67,159,173],"drugs":[21,99],"in":[22,31,35,41,79,91,178],"antimicrobial":[24,151,187],"pipeline":[26,43,93],"that":[27,39,171],"have":[28],"been":[29,76],"tested":[30],"vitro":[32],"and":[33,57,73,101,139,153],"evaluated":[34],"clinical":[36],"studies.":[37],"Antibiotics":[38],"are":[40,116,126,142,157],"for":[44,82,108],"treatment":[46,84],"serious":[48],"include":[52,94],"cephalosporins,":[54],"ceftobiprole,":[55],"ceftarolin":[56],"FR-264205.":[58],"Tigecycline":[59],"first":[62],"drug":[63,81],"approved":[64,98],"from":[65,191],"class":[68],"antibiotics":[70,118,169],"called":[71],"glycylcyclines,":[72],"there":[74],"has":[75],"renewed":[77],"interest":[78],"this":[80],"some":[86],"Carbapenems":[90],"tomopenem,":[95],"with":[96],"doripenem":[100],"faropenem,":[102],"oral":[104],"agent,":[105],"under":[106,163],"evaluation":[107],"activity":[109,132],"against":[110,133],"infections.":[114],"Polymyxins":[115],"old":[117],"traditionally":[119],"considered":[120],"to":[121],"be":[122],"toxic,":[123],"but":[124],"which":[125],"being":[127],"used":[128],"their":[131],"resistant":[134],"New":[137],"pharmacokinetic":[138],"pharmacodynamic":[140],"data":[141],"available":[143,177],"regarding":[144],"use":[146],"these":[148],"agents.":[149],"Finally,":[150],"peptides":[152],"efflux":[154],"pump":[155],"inhibitors":[156],"two":[158],"classes":[160],"agents":[162,174],"development.":[164],"This":[165],"review":[166],"investigational":[168],"shows":[170],"several":[172],"will":[175],"become":[176],"coming":[180],"years,":[181],"even":[182],"though":[183],"pace":[185],"research":[188],"far":[190],"ideal.":[192]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}